EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association between serum uric acid levels and galectin‐3 in patients with uncomplicated type 2 diabetes

Funda Yildirim Borazan iD, Ihsan Ergun, Tuba Candar, Ali Kemal Oguz

Internal Medicine Journal · 2025

DOI: 10.1111/imj.70070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Funda Yildirim Borazan und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Department of Internal Medicine, Ufuk University, Ankara, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Uric Acid, Galectin 3, Hyperuricemia. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serum uric acid (SUA) has been associated with an increased risk of cardiovascular disease (CVD) in both the general population and individuals with type 2 diabetes (T2DM). Identification of high‐risk individuals is crucial for the primary prevention of CVD. A growing array of newly discovered biomarkers has been identified for predicting CVD. Galectin‐3 (Gal‐3) is linked to inflammatory and fibrotic processes and has been suggested as a biomarker in patients with heart failure.

Aims

Our aim is to investigate whether Gal‐3 is a marker that may predict the risk of CVD caused by asymptomatic hyperuricemia in patients with uncomplicated T2DM.

Methods

Twenty patients (male/female: 10/10) with T2DM with high SUA levels and 20 controls (male/female: 10/10) matched for age and gender with T2DM with normal SUA levels were involved.

Results

SUA and Gal‐3 levels exhibited a statistically significant correlation ( r s = 0.33, P = 0.03). Although the high SUA group had higher Gal‐3 levels than the normal SUA group, the observed difference did not achieve statistical significance (mean: 18 (95% confidence interval (CI): 10.7–29)) vs 14.4 (95% CI: 10.4–30), P = 0.33)).

Conclusions

The present study is the first to show a correlation between the level of SUA and Gal‐3 in patients with uncomplicated T2DM. This result suggests that Gal‐3 could potentially serve as a marker to predict the risk of CVD in patients with uncomplicated T2DM with high SUA levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Uric AcidGalectin 3HyperuricemiaCardiovascular DiseasesHumansFemaleMaleMiddle AgedBiomarkersAgedAdultBlood ProteinsGalectins

Stichwörter der Autor:innen

biomarkercardiovascular diseasediabetesgalectin‐3serum uric acid

Substanzen

Uric AcidBiomarkersGalectin 3LGALS3 protein, humanBlood ProteinsGalectins

Autor:innen und Institutionen

  • School of Medicine, Department of Internal Medicine, Ufuk University, Ankara, Turkey.
  • School of Medicine, Department of Nephrology, Ufuk University, Ankara, Turkey.
  • School of Medicine, Department of Biochemistry, Ufuk University, Ankara, Turkey.

ORCID-Profile: Funda Yildirim Borazan

Zitieren

APA

Yildirim Borazan, F., Ergun, I., Candar, T., & Oguz, A. K. (2025). Association between serum uric acid levels and galectin‐3 in patients with uncomplicated type 2 diabetes. Internal Medicine Journal. https://doi.org/10.1111/imj.70070

Vancouver

Yildirim Borazan F, Ergun I, Candar T, Oguz AK. Association between serum uric acid levels and galectin‐3 in patients with uncomplicated type 2 diabetes. Internal Medicine Journal. 2025. doi:10.1111/imj.70070

BibTeX
@article{YildirimBorazan2025,
  author = {Yildirim Borazan, Funda and Ergun, Ihsan and Candar, Tuba and Oguz, Ali Kemal},
  title = {Association between serum uric acid levels and galectin‐3 in patients with uncomplicated type 2 diabetes},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.70070}
}
Kostenlos starten →